Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb 15;143(7):564-566.
doi: 10.1182/blood.2023023293.

Don't let the genie out of the bottle!

Shaji Kumar  1
Affiliations
Editorial

Don't let the genie out of the bottle!

Shaji Kumar. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.K. reports consulting/advisory board participation (with no personal payments) with AbbVie, BMS, Janssen, Roche-Genentech, Takeda, Pfizer, Loxo Oncology, K36, Sanofi, ArcellX, and Beigene.

Comment on

References

    1. Guerrero C, Puig N, Cedena M-T, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143(7):597–603. - PubMed
    1. D’Agostino M, Bertuglia G, Rota-Scalabrini D, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143(7):592–596. - PubMed
    1. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3(1):28–35. - PMC - PubMed
    1. Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood. 2012;120(5):1067–1076. - PMC - PubMed
    1. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. - PubMed